Is the Novacyt share price too high? Here’s what you need to know

The Novacyt share price is soaring after a strong H1 earnings announcement. But does that mean you should be buying?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Novacyt (LSE:NCYT) have been one of the few companies that has actually benefitted during 2020. Coronavirus has provided them with lucrative contracts for providing vital testing kits to the UK government. It’s no wonder that Novacyt shares have risen from 12p in 2019 to over 380p. At one point, the shares hit nearly 500p! And the Novacyt share price is moving up again after releasing a positive trading update this morning.

The results are in

The company has just released its H1 (first two quarters) results, announcing a pre-tax profit of €40.2m in the six months to 30 June, compared with a loss of €2m a year ago. Revenues were also up 900%. Not bad at all! EBITDA also rose – from €0.2m (2019 H1) to just under €50m. Directors believe demand will grow until “at least the first half of 2021” under the tense conditions presented by Covid-19.

The massive demand for PCR testing kits has of course been the main driver for these results and the rapid advancing of the Novacyt share price. And the company is looking to build upon its success. A new avenue is currently being explored in the launch of a diagnostic test designed to tell the difference between Covid-19 and the flu. This is well-timed, coinciding with the approaching winter flu season. So, the company is looking to the future. But what about the shares?

Is the Novacyt share price too high?

Full-year revenues are expected to exceed €150m and EBITDA to exceed €100m. For a company with a market cap of £280m, that’s a pretty strong performance if the guidance does play out as expected. But we must remember that 2020 has been an exceptional year and a very fortunate one for Novacyt. In 2019, the company recorded a net loss of £6.5m. In fact, 2020 will be the first year that will show any profits. If the Covid-19 threat dwindles (and that’s a big if), will Novacyt be able to sustain this year’s profitability?

Investors are always looking to the future. Part of the current price of a stock is always a judgement of the company’s future performance. The Novacyt share price is no different. The only way the stock can keep rising is by finding new avenues for profitability – especially in a post-Covid age. One hope is that the global contacts and networks that will be created during the pandemic will provide access to wider markets for other products in the future. The firm has repaid all its outstanding debts as well investing heavily in its inventory. Despite this, it was still left with €19.7m in cash flow as of 30 June.

It’s certainly possible that Novacyt could grow over the next few years into a profitable business that would justify the massive recent share price growth. At the same time, it’s also possible that 2020–21 was a brief period of fortune and the days of profit will disappear as quickly as they arrived. At this stage, in my opinion, you have probably missed the bargain that early 2020 provided.  

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Toby Aston has no position in any of the share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Is the S&P 500 going to 10,000 by 2030? This expert thinks so

One stock market strategist sees animal spirits taking hold and driving the S&P 500 index even higher by the end…

Read more »